Targeting diseases with genetically engineered Lactococcus lactis and its course towards medical translation

Expert Opinion on Biological Therapy

Volumn 11, Issue 3, 2011, Pages 261-267

  Villatoro Hernandez, Julio ^a   Montes De Oca Luna, Roberto ^c   Kuipers, Oscar P ^a,b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b KLUYVER CENTRE FOR GENOMICS OF INDUSTRIAL FERMENTATION   (Netherlands)

^c Medicina UANL   (Mexico)

Author keywords

biopharmaceuticals; human therapy; Lactococcus lactis; vaccine

Indexed keywords

CELL ANTIGEN; INTERLEUKIN 10; LACTOCOCCUS LACTIS VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; OUTER SURFACE PROTEIN A; STREPTOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; BACTERIAL STRAIN; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CROHN DISEASE; DRUG EFFICACY; ENDOPLASMIC RETICULUM; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLUENZA; LACTOCOCCUS LACTIS; MUCOSA INFLAMMATION; NONHUMAN; REVIEW; STREPTOCOCCUS PNEUMONIAE; ULCERATIVE COLITIS; VACCINATION;

BACTERIA (MICROORGANISMS); FLU VACCINE; LACTOCOCCUS LACTIS;

EID: 79851470191     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.542138     Document Type: Review

References (31)

1. Bermudez-Humaran LG. Lactococcus lactis as a live vector for mucosal delivery of therapeutic proteins. Hum Vaccin 2009;4:264-7
2. Van Huynegem K, Loos M, Steidler L. Immunomodulation by genetically engineered lactic acid bacteria. Front Biosci 2009;14:4825-35
3. Wells JM, Mercenier A. Mucosal delivery of therapeutic and prophylactic mole (Pubitemid 351552656)
4. Iwaki M, Okahashi N, Takahashi I, et al. Oral immunization with recombinant Streptococcus lactis carrying the Streptococcus mutans surface protein antigen gene. Infect Immun 1990;58:2929-34 (Pubitemid 20267682)
5. Mielcarek N, Alonso S, Locht C. Nasal vaccination using live bacterial vectors. Adv Drug Deliv Rev 2001;51:55-69 (Pubitemid 32763072)
6. Braat H, Rottiers P, Hommes DW, et al. A Phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 2006;4:754-9 (Pubitemid 43841860)
7. Steidler L, Neirynck S, Huyghebaert N, et al. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat Biotechnol 2003;21:785-9 (Pubitemid 36791397)
8. Vandenbroucke K, de Haard H, Beirnaert E, et al. Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol 2009;1:49-56
9. Hanniffy SB, Carter AT, Hitchin E, et al. Mucosal delivery of a pneumococcal vaccine using Lactococcus lactis affords protection against respiratory infection. J Infect Dis 2007;195:185-93 (Pubitemid 46080050)
10. De Ruyter PG, Kuipers OP, de Vos WM. Controlled gene expression systems for Lactococcus lactis with the food-grade inducer nisin. Appl Environ Microbiol 1996;62:3662-7 (Pubitemid 26329592)
11. Bermudez-Humaran LG, Cortes-Perez NG, Le Loir Y, et al. An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci. J Med Microbiol 2004;53:427-33 (Pubitemid 38586510)
12. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005;11:45-53
13. Yewdell JW. Not such a dismal science: the economics of protein synthesis, folding, degradation and antigen processing. Trends Cell Biol 2001;11:294-7 (Pubitemid 32537775)
14. Cuesta AM, Suarez E, Larsen M, et al. Enhancement of DNA vaccine potency through linkage of antigen to filamentous bacteriophage coat protein III domain I. Immunology 2006;117:502-6
15. Chen CH, Wang TL, Hung CF, et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 2000;60:1035-42
16. Kim JW, Hung CF, Juang J, et al. Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther 2004;11:1011-18 (Pubitemid 38923625)
17. Liao CW, Chen CA, Lee CN, et al. Fusion protein vaccine by domains of bacterial exotoxin linked with a tumor antigen generates potent immunologic responses and antitumor effects. Cancer Res 2005;65:9089-98
18. Loera-Arias MJ, Martinez-Perez AG, Barrera-Hernandez A, et al. Targeting and retention of HPV16 E7 to the endoplasmic reticulum enhances immune tumour protection. J Cell Mol Med 2010;14:890-4
19. Hung CF, Monie A, Alvarez RD, et al. DNA vaccines for cervical cancer: from bench to bedside. Exp Mol Med 2007;39:679-89
20. Lee P, Faubert GM. Expression of the Giardia lamblia cyst wall protein 2 in Lactococcus lactis. Microbiology 2006;152:1981-90 (Pubitemid 44070455)
21. Bermudez-Humaran LG, Cortes-Perez NG, Lefevre F, et al. A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J Immunol 2005;175:7297-302 (Pubitemid 41713425)
22. Steidler L, Rottiers P, Coulie B. Actobiotics as a novel method for cytokine delivery. Ann NY Acad Sci 2009;1182:135-45
23. Bosma T, Kanninga R, Neef J, et al. Novel surface display system for proteins on non-genetically modified Gram-positive bacteria. Appl Environ Microbiol 2006;72:880-9
24. van Roosmalen ML, Kanninga R, El Khattabi M, et al. Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria. Methods 2006;38:144-9 (Pubitemid 43163475)
25. Zechini B, Cipriani P, Papadopoulou S, et al. Endocarditis caused by Lactococcus lactis subsp. lactis in a patient with atrial myxoma: a case report. Diagn Microbiol Infect Dis 2006;56:325-8 (Pubitemid 44648593)
26. Pellizzer G, Benedetti P, Biavasco F, et al. Bacterial endocarditis due to Lactococcus lactis subsp. cremoris: case report. Clin Microbiol Infect 1996;2:230-2
27. Audouy SA, van Selm S, van Roosmalen ML, et al. Development of lactococcal GEM-based pneumococcal vaccines. Vaccine 2007;25:2497-506 (Pubitemid 46366131)
28. Mierau I, Kleerebezem M. 10 years of the nisin-controlled gene expression system (NICE) in Lactococcus lactis. Appl Microbiol Biotechnol 2005;68:705-17 (Pubitemid 41545614)
29. Kang TH, Kim KW, Bae HC, et al. Enhancement of DNA vaccine potency by antigen linkage to IFN-gamma-inducible protein-10. Int J Cancer 2010, doi: 10.1002/ijc.25391
30. Fuglsang A. Lactic acid bacteria as prime candidates for codon optimization. Biochem Biophys Res Commun 2003;312:285-91 (Pubitemid 37445170)
31. Mijakovic I, Petranovic D, Jensen PR. Tunable promoters in systems biology. Curr Opin Biotechnol 2005;16:329-35 (Pubitemid 40806471)